Type 1 diabetes, although the most common
|
|
- Scott Hawkins
- 5 years ago
- Views:
Transcription
1 ADDRESSING THE 21ST CENTURY DIABETES EPIDEMIC * Based on a presentation by David M. Nathan, MD ABSTRACT Type 2 diabetes is an epidemic disorder. Although its complications can be treated, prevented, or ameliorated through tight glycemic control, it is difficult and expensive to do so. As with many epidemics, prevention is essential. In the mid 1990s, the Diabetes Prevention Program (DPP) was implemented to identify potentially safe and effective therapies that may prevent type 2 diabetes. The patient population consisted of persons at high risk for diabetes; the goal was to prevent or slow the development of type 2 diabetes in overweight persons with impaired glucose tolerance. Compared with placebo, metformin and the intensive lifestyle regimen reduced the development of diabetes by 31% and 58%, respectively. In patients older than 60 years, the lifestyle regimen resulted in a 71% reduction in the development of diabetes. The DPP offered a novel approach to treating this epidemic. It has demonstrated that there are alternatives to this epidemic and that diabetes and its complications are not inevitable. We can stop diabetes before it develops. The question remains how to apply resources most effectively to accomplish this monumental task. (Advanced Studies in Medicine. 2002;2(26): ) *Based on a presentation given by Dr Nathan at the 84th Annual Meeting of the Endocrine Society. Address correspondence to: David M. Nathan, MD, Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, Diabetes Unit, 50 Staniford Street, 3rd floor, S50-3, Boston, MA Type 1 diabetes, although the most common chronic disease of childhood, has remained a relatively rare disorder, affecting probably no more than 1 million people in the United States. Type 2 diabetes is occurring in epidemic proportions nationwide; it affects nearly 8% of the population with approximately 16 to 17 million cases and new cases per year in the United States alone. The cause should be apparent to everyone: the epidemic of obesity. Data from the Nurses Health Study collected from more than nurses followed up for 16 years have demonstrated the effect of increased body mass index (BMI) on the development of diabetes mellitus. 1 The higher the weight, the greater the risk of developing diabetes. An additional risk is conferred as the waist-to-hip ratio increases. This phenomenon was first recognized more than 30 years ago and was recently corroborated by findings of the Iowa Women s Health Study. 2,3 The Physicians Health Study and others have shown that decreased activity levels are also associated with an increased risk of type 2 diabetes at almost every BMI quintile. 4 Finally, the advancing age of the population increases the risk in a large segment of the population. The burden imposed by diabetes is compounded by the complications associated with the disease. Type 2 diabetes is the most common cause of endstage renal disease in adults, blindness, and amputations in the United States. It carries a 2-fold to 5-fold increased risk for cardiovascular disease, and is associated with 40% of all cardiovascular disease in the United States. Advanced Studies in Medicine 961
2 Diabetes imparts an enormous cost in human lives and in dollars. Data from 1992 attributed more than $100 billion in medical costs annually to diabetes. 5 In other words, 15% of total healthcare expenditures were being accrued by 5% of the population. Bagust estimated the increase in diabetes over the course of the next 50 years with the general population and the working population (ages 20 through 59 years) growing at relatively slow rates. 6 The growth in the type 2 diabetes population is predicted to far outstrip the growth of the rest of the population, increasing at a rate of more than 115%. We are facing an epidemic of a chronic degenerative disease associated with profound health problems that increase over a lifetime, and a population that will not grow at a rate sufficient to pay the costs to care for the disease and its Much of the cost of diabetes is associated with the care of both microvascular and macrovascular We know from the Diabetes Control and Complications Trial (DCCT) and the Stockholm Diabetes Intervention study that intensive therapy is clearly merited for type 1 diabetes. 7,8 Therapy directed at controlling glucose levels in the near-normal range profoundly reduces the development of diabetes-specific Until the completion of the United Kingdom Prospective Diabetes Study (UKPDS), it was not known whether intensive therapy to normalize glucose levels in type 2 diabetes would reduce macrovascular or microvascular 9 The UKPDS, which began approximately 25 years ago, sought to determine whether an active policy of therapy with hypoglycemic medications, aimed at normalizing glycemia, was superior to the conventional dietary policy. The second major question addressed by this study was to determine whether any medications or treatment strategies had particular advantages over others. Type 2 diabetes patients were assigned to diet, sulfonylurea, or insulin, and if they were obese, to metformin. If therapy failed, other agents were added. The UKPDS successfully answered the first question. The hemoglobin A 1c (HbA 1c ) levels of patients receiving intensive therapy (insulin, sulfonylureas, or metformin) were lower than those receiving conventional treatment (Figure 1). 9 The UKPDS was able to improve the aggregate outcomes in type 2 diabetes. Intensive therapy reduced diabetes-related aggregate outcomes by 12% (P =.029); laser therapy outcomes by 29% (P =.003); and cataract extraction outcomes by 24% (P =.046). Overall, the UKPDS demonstrated the important long-term benefits of intensive therapy and established a similar association between glycemic levels and the risk for complications as in the DCCT. Managing type 2 diabetes, however, appeared to be more challenging than managing type 1 diabetes. In the UKPDS, glycemic levels rose progressively over time in the intensive treatment group, suggesting that type 2 diabetes is a progressive metabolic disorder. The UKPDS and the Kumamoto study that preceded it corroborated the findings of the DCCT that intensive therapy reduced the development and progression of Figure 1. UKPDS Results: Obese and Nonobese Patients Treated With Conventional Therapy vs Insulin/Sulfonylureas HbA 1c = hemoglobin A 1c. Adapted with permission from the UKPDS Study Group Vol. 2, No. 26 December 2002
3 most, if not all, diabetic 9,10 These studies established a metabolic goal for therapy and showed that lowering the HbA 1c level provided significant long-term benefits. The lower the glycemia, the lower the risk of HYPOGLYCEMIC AGENTS Several tools are available to assist us in lowering glycemia in type 2 diabetes, including diet, exercise, insulin, and hypoglycemic agents. In the UKPDS, it was possible to lower HbA 1c levels in patients with new-onset type 2 diabetes; however, levels rose progressively over time. Maintaining lower levels proved a constant battle. Do the new oral hypoglycemic agents contribute substantially to this battle? The glitinides, the alpha glucosidase inhibitors, and the thiazolidinediones may help to maintain lower HbA 1c levels; however, lacking long-term data, we cannot be sure whether they will prevent the worsening metabolic control seen in the UKPDS. In a study conducted by Horton et al, approximately 700 patients were randomly assigned to nateglinide, metformin, or a combination of the drugs. 11 From a baseline HbA 1c of 8.4%, nateglinide used as monotherapy lowered the HbA 1c merely 0.5%. Metformin proved somewhat more effective as monotherapy. Using nateglinide plus metformin, however, lowered the HbA 1c to 7%. Aronoff et al examined the efficacy of pioglitazone as monotherapy. 12 After maximal therapy (45 mg), the HbA 1c was lowered only to 9.4% from 10.3% at baseline. The thiazolidinediones may not be as effective as the older sulfonylureas or metformin when used as monotherapy; however, when used in combination (eg, combining rosiglitazone with metformin), the HbA 1c may decrease from 9% to 8% (Figure 2). 13 Although the newer agents are useful, they may not provide the long-term answer to the worsening glycemia in type 2 diabetes. Insulin remains an important treatment and has been used in numerous studies. 9,10,14,15 Aggressive insulin therapy in all of these studies successfully lowered HbA 1c levels to near 7%. Insulin clearly works. Unfortunately, physicians and patients are reluctant to use it at all or to use it in adequate doses. Insulin is often suggested to patients only after they have had diabetes for 10 or 15 years. At that time, glycemia has often been out of control for many years, and patients already have established Data from the UKPDS suggest we are at risk to lose this metabolic battle. The long-term complications of type 2 diabetes appear to be unrelenting. 9 Macrovascular disease accounts for the majority of complications in persons with type 2 diabetes. More than 75% of people with type 2 diabetes die from cardiovascular disease. PREVENTION Type 2 diabetes is an epidemic disorder. Although its complications can be treated, prevented, or ameliorated through tight glycemic control, it is quite difficult and expensive to do so. As with many epidemics, prevention is essential. The rationale for a prevention trial can be summarized in 3 points: The prevalence of type 2 diabetes is increasing in epidemic proportions, not only in the United States, but also throughout the world. When type 2 diabetes develops, it is difficult to treat; it is therefore difficult to prevent resulting Figure 2. Combination Therapy With Rosiglitazone Compared With Metformin HbA 1c = hemoglobin A 1c. *P <.001 compared with metformin alone. Adapted with permission from Fonseca et al. 13 Advanced Studies in Medicine 963
4 Prevention of type 2 diabetes would significantly reduce mortality and associated healthcare expenditures. In the mid 1990s, the Diabetes Prevention Program (DPP) was implemented to identify potentially safe and effective therapies that may prevent type 2 diabetes. 16,17 The patient population comprised persons at high risk for diabetes. Because most people who develop type 2 diabetes pass through an intermediate state of impaired glucose tolerance, such individuals were chosen as the research population. The goal of the DPP was to prevent or slow the development of type 2 diabetes in persons with impaired glucose tolerance. Eligibility was determined by having impaired glucose tolerance and being overweight. Eligible participants were randomized to 1 of 4 regimens: intensive lifestyle therapy (n = 1079), metformin (n = 1073), placebo (n = 1082), and troglitazone (n = 585), which was discontinued in June 1998 because of safety concerns. The lifestyle intervention regimen required following an intensive program with the following goals: weight loss of 7% or more, maintenance of weight loss, and 150 minutes or more per week of physical activity. A large number of racial and ethnic groups that are affected disproportionately by type 2 diabetes were purposely included in the study population (n = 3234). We included Caucasians (55%), African Americans (20%), Hispanic Americans (16%), Asian Americans and Pacific Islanders (4%), and Native Americans (5%). Long-term weight loss in this population had not been demonstrated in previous studies. In the DPP, however, subjects randomized to the intensive lifestyle regimen achieved their weight-loss goal (7 kg), representing more than a 7% loss of body mass. Over time, some weight was regained, resulting in an overall weight loss of 5% in 4 years. Subjects actually exercised more than recommended (30 minutes, 5 nights per week); they maintained 210 minutes of activity per week (30 minutes, 7 nights per week). Eleven percent of subjects randomized to placebo developed diabetes. Only 7.8% of subjects randomized to metformin and 4.8% of subjects randomized to the intensive lifestyle regimen developed diabetes. Compared with placebo, metformin and the intensive lifestyle regimen reduced the development of diabetes by 31% and 58%, respectively. The DPP interventions were successfully introduced in a variety of communities, and they were effective in all of them. Metformin did not work as well in the older population, but lifestyle worked surprisingly well, resulting in a 71% reduction in the development of diabetes in persons older than 60 years. This is particularly important because 20% of the population older than 60 years develops diabetes. In the younger population, metformin and lifestyle were similarly effective in reducing diabetes. The DPP offered a novel approach to treating this epidemic. It has demonstrated that there are alternatives to this epidemic and that diabetes and its complications are not inevitable. We can stop diabetes before it develops. The question remains how to apply resources most effectively to accomplish this monumental task. REFERENCES 1. Hu FB. Manson JE, Stampfer, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345: Andersson B, Terning K, Bjorntorp P. Dietary treatment of obesity localized in different regions. The effect of dietary fibre on relapse. Int J Obes. 1987;11(suppl 1): Folsom AR, Kushi LH, Anderson KE, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women s Health Study. Arch Intern Med. 2000;160: Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CM. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA. 1992;268: Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, J Clin Endocrinol Metab. 1994;78:809A-809F. 6. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of type 2 diabetes. Diabetologia. 2001;44: The Diabetes Control and Complications Trial. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329: Reichard P, Britz A, Carlsson P, et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). J Intern Med. 1990;228: United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or 964 Vol. 2, No. 26 December 2002
5 insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus (UKPDS 33). Lancet. 1998;352: Ohkubo Y, Kishikawa H, Awaki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28: Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23: Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23: Fonseca B, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283: Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type 2 diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in type 2 diabetes. Diabetes Care. 1995;18: Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care. 1995;18: The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22: Knowler WC, Barrett-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346: Advanced Studies in Medicine 965
Managing Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More informationDiabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.
Health Care Disparities: Medical Evidence Diabetes Effects 2.8 Million People in US 7% of the US Population Sixth Leading Cause of Death Kenneth J. Steier, DO, MBA, MPH, MHA, MGH Dean of Clinical Education
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationDiabetes is a metabolic disorder primarily
P O S I T I O N S T A T E M E N T Implications of the United Kingdom Prospective Diabetes Study AMERICAN DIABETES ASSOCIATION Diabetes is a metabolic disorder primarily characterized by elevated blood
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationOverweight is defined as a body mass
THE DANGEROUS LIAISON: WEIGHT GAIN AND ITS ASSOCIATED COMORBIDITIES * Zachary T. Bloomgarden, MD ABSTRACT Overweight and obesity have tangible physical consequences that affect mortality and economics,
More informationDiabetes Overview. How Food is Digested
Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationThe Diabetes Prevention Program: Call for Action
The Diabetes Prevention Program: Call for Action Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management, Joslin Diabetes Center Harvard Medical
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationInitiation and Adjustment of Therapy in Type 2 Diabetes
Initiation and Adjustment of Therapy in Type 2 Diabetes a report by The American Diabetes Association DOI: 10.17925/USE.2007.00.1.15 This article is a synopsis of a consensus statement published in 2006
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationSetting The setting was not explicitly stated. The economic study was carried out in the UK.
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK Beale S, Bagust A, Shearer A T, Martin A, Hulme L Record Status This is a critical abstract
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More information1. Introduce the Culture of Health Framework. 2. Become acquainted with the the Robert Wood Johnson Foundation Public Health Nurse Leadership Program
1. Introduce the Culture of Health Framework. 2. Become acquainted with the the Robert Wood Johnson Foundation Public Health Nurse Leadership Program (PHNL). 3. Increase awareness of diabetes/prediabetes
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationMedia Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)
News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationChoosing a Diabetes Strategy Where to Start and Where to Go
Choosing a Diabetes Strategy Where to Start and Where to Go Erin Keely, MD, FRCPC; and Sharon Brez, RN, BScN, MA(Ed), CDE As presented at the University of Ottawa's 52nd Annual Refresher Course for Family
More informationChanging the Course of Diabetes: Turning Hope into Reality
Indian Health Service Special Diabetes Program for Indians 2014 Report to Congress Changing the Course of Diabetes: Turning Hope into Reality In response to the burgeoning diabetes epidemic among American
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationFinding the sweet spot: Individualized targets for older adults with Type 2 DM
Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationAddressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:
Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her
More informationWhat s New. in Clinical Research
What s New in Clinical Research This new department features articles discussing recent developments in drug therapy, as well as review articles on specific drug therapies or disease states. Articles will
More informationDiabetes Mellitus is defined as a clinical
ProceedbzgS.Z.P.G.M.I. vol: 17(2): pp. 99-/05, 2003. Global Epidemic of Diabetes Mellitus - An Overview Farrukh lq bal Department of Internal Medicine, Shaikh Zayed Postgraduate Medical Institute, Lahore.
More informationThe Global Agenda for the Prevention of Diabetes: Research Opportunities
The Global Agenda for the Prevention of Diabetes: Research Opportunities William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationMetformin is the only drug. Sustained release metformin where standard metformin is not tolerated. Julie Brake
Sustained release metformin where standard metformin is not tolerated Julie Brake Article points 1. Few people will continue taking medication while experiencing side effects. 2. Hypoglycaemia does not
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationFixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University
Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More information3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH
3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH 1.1 Introduction Ivana Pavlić-Renar, Ph.D. Vuk Vrhovac University Clinic, Zagreb, Croatia The current classification of
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationDonna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico
Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Presented in Collaboration with New Mexico Health Care Takes On Diabetes Discuss the burden and challenges prediabetes presents in New Mexico.
More information1,2,3 1. Diabetes in the Latino Population: A Case-based Approach to Optimal Management. Why Are We Concerned about Diabetes Among Latinos?
Diabetes in the Latino Population: A Case-based Approach to Optimal Management 1 Learner Objectives Upon completion, attendees should be able to: List the medical, social, and economic ways in which diabetes
More informationCE on SUNDAY Newark, NJ October 18, 2009
CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 2:45 PM 3:45 PM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Addressing Challenges in Type 2 Diabetes ACPE #
More informationA Guidance Statement from the American College of Physicians
Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationDiabetes Care begins with Diabetes Prevention. Neha Sachdev, MD Janet Williams, MA
Diabetes Care begins with Diabetes Prevention Neha Sachdev, MD Janet Williams, MA Objectives Describe the clinical practice burden and trends in type 2 diabetes Review evidence for diabetes prevention
More informationDiabetes 101: A Brief Overview of Diabetes and the American Diabetes Association
Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat? After eating, most food is turned into glucose, the body s main source of energy. Normal Blood
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationWhen and how to start insulin therapy in type 2 diabetes
When and how to start insulin therapy in type 2 diabetes Anne Kilvert MD, FRCP Most patients with type 2 diabetes will eventually require insulin due to the progressive decline in betacell function. Dr
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationDiabetes Pathophysiology and Treatment Strategies
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Diabetes Pathophysiology and Treatment Strategies Beth Careyva MD Lehigh Valley Health Network, beth_a.careyva@lvhn.org Follow
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationNational Diabetes Fact Sheet, 2011
National Diabetes Fact Sheet, 2011 FAST FACTS ON DIABETES Diabetes affects 25.8 million people 8.3% of the U.S. population DIAGNOSED 18.8 million people UNDIAGNOSED 7.0 million people All ages, 2010 Citation
More informationIt s Never Too Early To Prevent Diabetes: The Lasting Impact of Gestational Diabetes on Mothers and Children
It s Never Too Early To Prevent Diabetes: The Lasting Impact of Gestational Diabetes on Mothers and Children Robert Ratner, M.D., F.A.C.P. Vice President for Scientific Affairs, Medstar Research Institute
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationA1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs
Butler University Digital Commons @ Butler University Undergraduate Honors Thesis Collection Undergraduate Scholarship 5-2017 A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs Shelby
More informationDavid M. Nathan, M.D. January, 2018
David M. Nathan, M.D. January, 2018 David M. Nathan, M.D. has only one conflict of interest. He is currently conducting an investigatorinitiated study of a point-of-care HbA1c device that has been funded
More informationWhy do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?
What is Diabetes? Diabetes 101 Ginny Burns RN MEd CDE Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationHelpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center
Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is
More informationDisclosures. Type 2 Diabetes. The New Epidemic: How Did We Get Here and What's to Come? Summary:
Type 2. The New Epidemic: How Did We Get Here and What's to Come? Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco None Disclosures robert.rushakoff@ucsf.edu Type 2.
More informationDiabetes is a condition with a huge health impact in Asia. More than half of all
Interventions to Change Health Behaviors and Prevention Rob M. van Dam, PhD Diabetes is a condition with a huge health impact in Asia. More than half of all people with diabetes live today in Asian countries,
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationImprovement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires
diabetes research and clinical practice 81 (2008) 169 178 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/diabres Improvement of glycemic control and quality-of-life by insulin
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationDiabetes 101: A Brief Overview of Diabetes and the American Diabetes Association
Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat? After eating, most food is turned into glucose, the body s main source of energy. Normal Blood
More informationEnergy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationImplementing Type 2 Diabetes Prevention Programmes
Implementing Type 2 Diabetes Prevention Programmes Jaakko Tuomilehto Department of Public Health University of Helsinki Helsinki, Finland FIN-D2D Survey 2004 Prevalence of previously diagnosed and screen-detected
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationVolume : 05 Issue : 03 July-Sept Pages:
Middle East Journal of Applied Sciences Volume : 05 Issue : 03 July-Sept. 2015 Pages: 695-699 Efficacy and Safety of Vildagliptin as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Poorly Controlled
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More information